Clinical Takeaway
In this phase 3 randomized controlled trial, 820 adults with chronic low back pain were treated with VER-01, a full-spectrum cannabis extract, over a 12-week blinded period followed by up to a year of extended follow-up. The trial was designed to rigorously assess both efficacy and safety at a scale that meets regulatory standards for evidence. Results from this study contribute meaningful clinical data on whether a standardized cannabis-based medicine can serve as a viable alternative to existing pharmacologic options for this highly prevalent and difficult-to-treat condition.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical therapeutic gap in chronic low back pain management, where current pharmacologic options demonstrate limited efficacy and carry significant adverse effect profiles, including opioid-related risks. A rigorously designed, adequately powered study demonstrating efficacy and safety of a full-spectrum cannabis extract could provide clinicians with an evidence-based alternative for a condition affecting over 500 million people globally. The extended open-label phase and focus on a standardized extract (VER-01) offer valuable data on both short-term efficacy and longer-term safety outcomes necessary to inform clinical decision-making and establish dosing guidelines.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial of VER-01, a full-spectrum cannabis extract, adds meaningful data to our limited evidence base for cannabinoid treatment of chronic low back pain, a condition where conventional analgesics often fall short. The study’s size and structure are commendable, though practitioners should note that full-spectrum extracts contain variable cannabinoid and terpene ratios, which may affect both efficacy and tolerability in ways that complicate generalization to other products. Key considerations include the specific dosing regimen used, baseline pain severity and functional status of participants, and whether improvements persisted in the open-label extension phase, as placebo effects and natural fluctuations in back pain are particularly robust in this population. The safety profile compared to opioids is potentially significant, but clinicians should still counsel patients on dose titration, driving safety, and potential interactions with other medications. If this trial demonstrates clinically meaningful pain reduction and acceptable safety, VER-01 could reasonably be considered as part of a multi